pyrazines has been researched along with selexipag in 125 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (2.40) | 29.6817 |
| 2010's | 81 (64.80) | 24.3611 |
| 2020's | 41 (32.80) | 2.80 |
| Authors | Studies |
|---|---|
| Asaki, T; Hamamoto, T; Hashino, A; Kuwabara, K; Kuwano, K; Okubo, K; Yamada, T | 1 |
| Asaki, T; Nakamura, A; Yamada, T | 1 |
| Hashino, A; Kosugi, K; Kuwabara, K; Kuwano, K; Noda, K | 1 |
| Clozel, M; Ernst, R; Hess, P; Morrison, K; Studer, R | 1 |
| Bonderman, D; Degano, B; Delcroix, M; Efficace, M; Galiè, N; Giorgino, R; Hoeper, MM; Karlócai, K; Kurzyna, M; Lang, IM; Simonneau, G; Torbicki, A | 1 |
| Clozel, M; Ernst, R; Haag, F; Kauser, K; Morrison, K; Studer, R | 1 |
| Kovacs, G; Olschewski, H | 1 |
| Morrell, N; Sitbon, O | 1 |
| Clapp, LH; Ledwozyw, A; Orie, NN; Whittle, BJ; Williams, DJ | 1 |
| Lang, IM; Skoro-Sajer, N | 1 |
| Bruderer, S; Dingemanse, J; Hurst, N; Kaufmann, P | 1 |
| Bruderer, S; Darpo, B; Dingemanse, J; Hoch, M; Kaufmann, P; Remenova, T; Stoltz, R; Zhou, M | 1 |
| Bruderer, S; Dingemanse, J; Kaufmann, P; Mant, T; Mukai, H; Okubo, K; Yamada, T | 1 |
| Äänismaa, P; Bruderer, S; Dingemanse, J; Halabi, A; Kaufmann, P; Niglis, S; Segrestaa, J | 1 |
| Baldoni, D; Bruderer, S; Dingemanse, J; Muhsen, N | 1 |
| Asaki, T; Clozel, M; Gatfield, J; Hamamoto, T; Kuwano, K; Morrison, K | 1 |
| Sharma, K | 1 |
| Adzerikho, I; Channick, R; Chin, KM; Di Scala, L; Frey, A; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; Liu, J; McLaughlin, VV; Moiseeva, O; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, V; Zeng, X | 1 |
| Amar, D; Boucly, A; Chaumais, MC; Humbert, M; Jaïs, X; Montani, D; O'Connell, C; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Scott, LJ | 1 |
| Advani, A; Advani, SL; Azizi, PM; Batchu, SN; Bowskill, BB; Brijmohan, AS; Lee, WL; Liu, Y; Majumder, S; Thai, K; White, KE | 1 |
| Cruz, HG; Dingemanse, J; Halabi, A; Kaufmann, P; Krause, A; Ulč, I | 1 |
| Bruderer, S; Dingemanse, J; Mant, T; Mukai, H; Okubo, K | 1 |
| Channick, RN; Tamura, Y | 1 |
| Gall, H; Ghofrani, HA; Grimminger, F; Grimminger, J; Richter, MJ | 1 |
| Horn, EM; Krishnan, U | 1 |
| Adams, H; Prior, DL; Williams, TJ | 1 |
| Ball, S; Bandyopadhyay, D; Das, A; Ghosh, RK; Gupta, A; Mondal, S; Saha, D | 1 |
| Farber, HW; Moll, M; Sardana, M | 1 |
| Astruc, B; Dingemanse, J; Hurst, N; Kaufmann, P | 1 |
| Chin, KM; Hardin, EA | 1 |
| Allanore, Y; Bruni, C; Distler, O; Gabrielli, A; Iannone, F; Matucci-Cerinic, M; Praino, E | 1 |
| Kaluski, E; Mishra, A; Singh, M | 1 |
| Fuchikami, C; Homan, J; Kosugi, K; Kuramoto, K; Kuwano, K; Murakami, K; Oka, M; Tajima, K | 1 |
| Burness, CB; Duggan, ST; Keam, SJ | 1 |
| Gnerre, C; Ichikawa, T; Nonaka, K; Treiber, A; Yamada, T | 1 |
| Del Pozo, R; Escribano-Subias, P; Hernandez Gonzalez, I | 1 |
| Anzai, T; Fukuda, K; Hashimoto, A; Hatano, M; Ikeda, S; Inoue, T; Ito, H; Kajinami, K; Kihara, Y; Kinoshita, H; Kuwahara, K; Murohara, T; Nakayama, T; Okazaki, O; Sakai, S; Sasayama, S; Satoh, T; Tahara, N; Takeda, Y; Takeishi, Y; Tanabe, N; Taniguchi, M; Watanabe, H; Yamamoto, T; Yamauchi-Takihara, K; Yoshioka, K | 1 |
| Clozel, M; Gatfield, J; Gnerre, C; Hess, P; Iglarz, M; Menyhart, K; Monnier, L; Morrison, K; Nayler, O; Wanner, D | 1 |
| Baker, WL; Darsaklis, K; Salerno, EL; Singhvi, A | 1 |
| Bruderer, S; Dingemanse, J; Hurst, N; Remenova, T | 1 |
| Bates, RE; Frantz, RP; Thurber, KM; Williams, BM | 1 |
| Honorato Pérez, J | 1 |
| Kido, K; Macaulay, TE; Noel, ZR | 1 |
| Bruderer, S; Dingemanse, J; Hurst, N; Krause, A; Lott, D; Machacek, M | 1 |
| Boehler, M; Bruderer, S; Dingemanse, J; Donazzolo, Y; Juif, PE | 1 |
| Boehler, M; Bruderer, S; Dingemanse, J; Ulč, I | 1 |
| Alejos, J; Drogalis-Kim, DE; Gallotti, R; Satou, G | 1 |
| Boehler, M; Bruderer, S; Dingemanse, J; Halabi, A; Petersen-Sylla, M; Remeňová, T | 1 |
| Äänismaa, P; de Kanter, R; Delahaye, S; Gnerre, C; Ichikawa, T; Pfeifer, T; Seeland, S; Segrestaa, J; Treiber, A; Yamada, T | 1 |
| Hansmann, G; Koestenberger, M | 1 |
| Channick, R; Chin, K; Coghlan, G; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, V; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Seibold, JR; Wigley, FM | 1 |
| Grimm, D; Infanger, M; Kruger, M; Nassef, MZ; Simonsen, U; Sorensen, LM; Wehland, M | 1 |
| Dutt, M; Feldman, J; Habib, N; Radosevich, J | 1 |
| Hussar, DA | 1 |
| El Yafawi, R; Wirth, JA | 1 |
| Furukawa, A; Goto, M; Iwahori, H; Kawamura, A; Ohashi, N; Okabe, T; Tamura, Y | 1 |
| Channick, RN; Chin, K; Di Scala, L; Farber, HW; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Preston, IR; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Denton, CP; Frenoux, JM; Frey, A; Hachulla, É; Herrick, AL; Le Brun, FO; Riemekasten, G; Schwarting, A | 1 |
| Channick, R; Chin, K; Coghlan, JG; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, V; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Gnerre, C; Ichikawa, T; Nonaka, K; Seeland, S; Segrestaa, J; Treiber, A; Yamada, T | 1 |
| Denton, CP; Herrick, AL | 1 |
| Domsic, RT; Pauling, JD; Saketkoo, LA | 1 |
| Greene, RA | 1 |
| Noel, ZR | 1 |
| Clozel, M; Ernst, R; Haag, F; Iglarz, M; Morrison, K | 1 |
| Brizzolara, R; Corallo, C; Cutolo, M; Giordano, N; Montagna, P; Paolino, S; Parodi, A; Pizzorni, C; Ruaro, B; Scabini, S; Smith, V; Soldano, S; Stratta, E; Sulli, A; Tavilla, PP; Trombetta, AC | 1 |
| Boerema-de Munck, A; Burgisser, PE; Buscop-van Kempen, MJ; Dzyubachyk, O; Kool, HM; Mous, DS; Nagata, K; Rottier, RJ; Tibboel, D; van Rosmalen, J; Wijnen, RMH | 1 |
| Ecker-Schlipf, B | 1 |
| Akerström, F; Berenguel Senén, A; Escribano Subías, P; Lázaro Salvador, M; Martinez Mateo, V; Rodriguez Padial, L | 1 |
| Ichikawa, T; Imai, S; Nonaka, K; Sugiyama, C; Yamada, T | 1 |
| Fanous, SM; Janmohamed, M | 1 |
| Benza, RL; Chin, KM; Eggert, M; Farber, HW; Fisher, M; Fortin, TA; Fritz, JS; Frost, A; Janmohamed, M; Kim, NH; McConnell, JW; McEvoy, C; McLaughlin, V; Miller, CE; Pfister, T; Poch, D; Shiraga, Y | 1 |
| Ais, A; Beaudet, A; Gil, A; Jiménez, A | 1 |
| Beghetti, M; Channick, RN; Chin, KM; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Airhart, S; Badie, N; Benza, R; Raina, A; Verlinden, N | 1 |
| Escribano Subías, P; Lázaro Salvador, M; Rodriguez Padial, L | 1 |
| Berlier, C; Lichtblau, M; Saxer, S; Schwarz, EI; Ulrich, S | 1 |
| Channick, R; Chin, KM; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Bock, MJ; Koo, R; Lo, J | 1 |
| Braverman, LE; Farber, HW; Menon, AA; Sahay, S | 1 |
| Jin, Q; Liu, Z; Luo, Q; Xiong, C; Yan, L; Yu, X; Zhang, Y; Zhao, Q; Zhao, Z | 1 |
| Dahhan, T; Doerfler, S; Fortin, T; Kennedy, K; Parikh, KS; Rajagopal, S; Shelburne, N; Whitson, J | 1 |
| Benet, J; Bouvaist, H; Degano, B; Guillien, A; Picard, F; Piliero, N; Pison, C; Sitbon, O; Soumagne, T; Yanaka, K | 1 |
| Bialesova, L; Bouchard, A; Kinsella, BT; Mulvaney, EP; Reid, HM; Salvail, D | 1 |
| Lachant, DJ; White, RJ | 1 |
| Bukova, M; Chouvarine, P; Hansmann, G; Koestenberger, M; Meinel, K; Wåhlander, H | 1 |
| Goncharova, NS; Karelkina, EV; Moiseeva, OM; Simakova, MA | 1 |
| Axelsen, LN; Bruderer, S; Perez Ruixo, JJ; Poggesi, I; Rasschaert, F | 1 |
| Chan, KC; Das, BB; Jadotte, MM | 1 |
| Burgos-Blasco, P; Diaz-Guimaraens, B; Dominguez-Santas, M; Ortega-Quijano, D; Saceda-Corralo, D; Suarez-Valle, A | 1 |
| DeChristopher, A; Fann, J; Feldman, J; Irandost, M; Radosevich, JJ | 1 |
| Amin, EK; Austin, ED; Colglazier, E; Fineman, JR; Hemnes, AR; Leary, PJ; Nawaytou, H; Parker, C; Teitel, D | 1 |
| Chen, J; Shi, L; Xie, S; Xu, RA; Ye, X | 1 |
| Burki, TK | 1 |
| Boutou, A; Panagiotidou, E; Pitsiou, G | 1 |
| Adachi, S; Kondo, T; Nakano, Y | 1 |
| Benza, RL; Raina, A; Verlinden, NJ; Walter, C | 1 |
| Hakamata, A; Inui, N; Kamiya, C; Katayama, N; Namiki, N; Odagiri, K; Tanaka, S; Tatsumi, K; Uchida, S; Watanabe, H | 1 |
| Fuchikami, C; Honda, Y; Kosugi, K; Kuramoto, K; Kuwano, K; Numakura, Y | 1 |
| Bernardo Reyes, AW; Kim, HJ; Kim, S; Lee, HJ; Lee, JH; Min, W; Ngoc Huy, TX; Vu, SH | 1 |
| Beghetti, M; Genecand, L; Lador, F; Wacker, J | 1 |
| Chakinala, MM; Chin, KM; Farber, HW; Hemnes, AR; Highland, KB; Kim, NH; McLaughlin, V; Narayan, V; Zhao, C | 1 |
| Axelsen, LN; Chin, KM; Ewert, R; Gall, H; Hsu Schmitz, SF; Klose, H; Parambil, J; Poch, D; Preston, IR; Seyfarth, HJ; Stein, C | 1 |
| Apostolopoulou, SC; Demerouti, EA; Karyofyllis, P | 1 |
| Channick, RN; Chin, KM; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, I; McLaughlin, VV; Preiss, R; Rubin, LJ; Sauter, R; Simonneau, G; Sitbon, O; Tapson, V | 1 |
| Lafuente-Romero, A; Rodriguez Ogando, A | 1 |
| Amara Babu, NLA; Koganti, K; Palakeeti, B; Rao, KP; Srinivas, KSV | 1 |
| Berkson, L; Chartrand, S; Langleben, D | 1 |
| Chin, KM; Doelberg, M; Feldman, J; Galiè, N; Gibbs, JSR; Grünig, E; Hoeper, MM; Martin, N; Mathai, SC; McLaughlin, VV; Perchenet, L; Poch, D; Saggar, R; Simonneau, G; Sitbon, O | 1 |
| Channick, R; Chin, KM; Coghlan, JG; Gaine, S; Galiè, N; Hoeper, MM; Hsu Schmitz, SF; Lang, IM; Lassen, C; McLaughlin, VV; Rubin, LJ; Sitbon, O; Tapson, VF | 1 |
| Avdeev, SN; Nekludova, GV; Proshkina, AA; Tsareva, NA | 1 |
| Channick, R; Chin, KM; Du Roure, C; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Jenner, B; Lang, IM; McLaughlin, VV; Rosenkranz, S; Rubin, LJ; Sitbon, O; Tapson, V | 1 |
| Maeder, MT | 1 |
| Abe, K; Ako, J; Ikeda, Y; Joho, S; Kinoshita, H; Maki, H; Matoba, S; Motoki, H; Ogo, T; Saeki, T; Sakao, S; Shimokawahara, H; Shiota, N; Sugano, T; Takama, N; Tanabe, N; Tanaka, S; Tatsumi, K; Tsujino, I; Yamamoto, C; Yoshioka, K | 1 |
| Chen, M; Chen, R; Hong, C; Lai, Y; Liu, H; Lu, J; Wang, D; Zhang, Y; Zheng, Z; Zhong, Y | 1 |
| Chen, YA; Fan, C; Gu, EM; Luo, SB; Xu, RA; Zhou, SC | 1 |
| Akashi, K; Arinobu, Y; Ayano, M; Fukata, M; Higashioka, K; Horiuchi, T; Imabayashi, K; Kashiwado, Y; Kawano, S; Kimoto, Y; Mitoma, H; Niiro, H; Ono, N; Saiki, C; Yokoyama, T | 1 |
| Chen, H; Li, C; Liang, Y; Qiu, Y; Shen, Y; Xu, M | 1 |
| Ghofrani, HA | 1 |
| Liang, L; Ma, G; Wang, D; Xu, L; Xu, X | 1 |
| Chouvarine, P; Diedrich, N; Diekmann, F; Hansmann, G; Hasan, H; Koestenberger, M | 1 |
| Blanco, I; Cruz Utrilla, A; Del Pozo, R; Escribano-Subías, P; López-Meseguer, M | 1 |
26 review(s) available for pyrazines and selexipag
| Article | Year |
|---|---|
Pathways in pulmonary arterial hypertension: the future is here.
Topics: Acetamides; Animals; Antihypertensive Agents; Benzamides; Clinical Trials as Topic; Drugs, Investigational; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Epoprostenol; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lisuride; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Serotonin Antagonists; Sulfonamides | 2012 |
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines; Receptors, Prostaglandin; Signal Transduction | 2014 |
Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension.
Topics: Acetamides; Epoprostenol; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Prostaglandin | 2016 |
Selexipag: First Global Approval.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic; Drug Approval; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Prostaglandin | 2016 |
New paradigm for pulmonary arterial hypertension treatment.
Topics: Acetamides; Antihypertensive Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Inositol 1,4,5-Trisphosphate Receptors; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyrazines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides | 2016 |
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Animals; Drug Approval; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines | 2016 |
A Contemporary Approach to Pulmonary Arterial Hypertension.
Topics: Acetamides; Antihypertensive Agents; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Pyrazines; Pyrimidines; Sulfonamides | 2016 |
Update on pharmacotherapy for pulmonary hypertension.
Topics: Acetamides; Antihypertensive Agents; Australia; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides; World Health Organization | 2016 |
Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies.
Topics: Acetamides; Animals; Antihypertensive Agents; Drug Interactions; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Animals; Antihypertensive Agents; Delayed-Action Preparations; Drug Evaluation, Preclinical; Humans; Hypertension, Pulmonary; Pyrazines; Treatment Outcome | 2016 |
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pyrazines; Tachyphylaxis | 2016 |
Use of biologics and other novel therapies for the treatment of systemic sclerosis.
Topics: Abatacept; Acetamides; Antibodies, Monoclonal, Humanized; Biological Products; Clinical Trials as Topic; Fibrinolytic Agents; Fibrosis; Humans; Hypertension, Pulmonary; Indoles; Inflammation; Joints; Lisuride; Lung; PubMed; Pyrazines; Pyrazoles; Pyrimidines; Scleroderma, Systemic; Skin | 2017 |
The year since the guidelines: a concise update on recent advances in pulmonary hypertension.
Topics: Acetamides; Algorithms; Guidelines as Topic; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Pyrazines; Vasodilator Agents | 2017 |
Selexipag: A Review in Pulmonary Arterial Hypertension.
Topics: Acetamides; Antihypertensive Agents; Clinical Trials as Topic; Gastrointestinal Diseases; Headache; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol | 2017 |
Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
Topics: Acetamides; Costs and Cost Analysis; Hospitalization; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines | 2017 |
Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Adult; Animals; Antihypertensive Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Topics: Acetamides; Acetates; Administration, Oral; Animals; Antihypertensive Agents; Drug Design; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol | 2017 |
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Hospitalization; Humans; Hypertension, Pulmonary; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Topics: Acetamides; Animals; Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension, Pulmonary; Prodrugs; Pyrazines; Treatment Outcome | 2017 |
Oral treprostinil in the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic; Drug Approval; Epoprostenol; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Pyrazines; Receptors, Prostaglandin; Treatment Outcome | 2017 |
What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?
Topics: Acetamides; Adult; Anticoagulants; Antihypertensive Agents; Cardiac Catheterization; Disease Progression; Diuretics; Drug Therapy, Combination; Echocardiography, Doppler; Endothelin Receptor Antagonists; Enzyme Activators; Exercise Tolerance; Female; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Prostaglandins; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pulmonary Edema; Pulmonary Veno-Occlusive Disease; Pyrazines; Pyrazoles; Pyrimidines; Retrospective Studies; Walk Test | 2019 |
An evaluation of selexipag for the treatment of pulmonary hypertension.
Topics: Acetamides; Administration, Oral; Adult; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Humans; Pulmonary Arterial Hypertension; Pyrazines | 2021 |
Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol | 2022 |
31 trial(s) available for pyrazines and selexipag
| Article | Year |
|---|---|
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Adult; Aged; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Receptors, Epoprostenol; Receptors, Prostaglandin; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2012 |
Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects.
Topics: Acetamides; Acetates; Administration, Oral; Adult; Double-Blind Method; Healthy Volunteers; Humans; Male; Maximum Tolerated Dose; Middle Aged; Platelet Aggregation; Pyrazines; Receptors, Epoprostenol | 2014 |
A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist.
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Placebos; Pyrazines; Receptors, Epoprostenol; Receptors, Prostaglandin; Young Adult | 2015 |
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Food-Drug Interactions; Half-Life; Humans; Male; Pyrazines; Receptors, Epoprostenol; Young Adult | 2015 |
Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.
Topics: Acetamides; Acetates; Adult; Antihypertensive Agents; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Healthy Volunteers; Humans; Lopinavir; Male; Middle Aged; Pyrazines; Ritonavir; Young Adult | 2015 |
Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study.
Topics: Acetamides; Adult; Cross-Over Studies; Humans; Male; Prospective Studies; Pyrazines; Receptors, Epoprostenol; Tablets; Therapeutic Equivalency | 2015 |
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Topics: Acetamides; Aged; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Prodrugs; Pyrazines | 2015 |
Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
Topics: Acetamides; Acetates; Adult; Aged; Antihypertensive Agents; Area Under Curve; Case-Control Studies; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Prospective Studies; Pyrazines; Receptors, Epoprostenol; Severity of Illness Index | 2016 |
Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects.
Topics: Acetamides; Acetates; Adolescent; Adult; Anticoagulants; Cross-Over Studies; Double-Blind Method; Drug Interactions; Humans; International Normalized Ratio; Male; Middle Aged; Pyrazines; Warfarin; Young Adult | 2016 |
Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist.
Topics: Acetamides; Acetates; Administration, Oral; Adult; Antihypertensive Agents; Biological Availability; Cross-Over Studies; Humans; Infusions, Intravenous; Male; Pyrazines; Receptors, Epoprostenol; Receptors, Prostaglandin; Young Adult | 2017 |
Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
Topics: Acetamides; Adult; Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung; Male; Middle Aged; Pyrazines; Receptors, Epoprostenol | 2017 |
Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
Topics: Acetamides; Acetates; Adult; Antihypertensive Agents; Bilirubin; Double-Blind Method; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Leukocyte Count; Male; Models, Biological; Natriuretic Peptide, Brain; Peptide Fragments; Pyrazines; Treatment Outcome | 2017 |
A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
Topics: Acetamides; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Half-Life; Healthy Volunteers; Humans; Male; Midazolam; Pyrazines; Young Adult | 2017 |
Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.
Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Male; Middle Aged; Pyrazines; Therapeutic Equivalency; Young Adult | 2018 |
Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
Topics: Acetamides; Acetates; Activation, Metabolic; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Drug Interactions; Gemfibrozil; Germany; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Middle Aged; Prodrugs; Pyrazines; Rifampin; Risk Assessment; Young Adult | 2017 |
The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag.
Topics: Acetamides; Acetates; Drug Interactions; Enzyme Inhibitors; Esterases; Hepatocytes; Humans; Membrane Transport Proteins; Metabolic Networks and Pathways; Metabolome; Metabolomics; Microsomes, Liver; NADP; Pyrazines; Receptors, Epoprostenol; Recombinant Proteins; RNA, Messenger | 2018 |
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Risk Assessment; Scleroderma, Systemic; Survival Analysis | 2017 |
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Receptors, Epoprostenol; Time Factors; Withholding Treatment | 2018 |
Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
Topics: Acetamides; Adult; Antihypertensive Agents; Bayes Theorem; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyrazines; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Treatment Outcome | 2017 |
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Diarrhea; Double-Blind Method; Drug Delivery Systems; Drug Therapy, Combination; Epoprostenol; Female; Headache; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Signal Transduction | 2018 |
[In process].
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Substitution; Drug Tolerance; Epoprostenol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prodrugs; Prospective Studies; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Treatment Outcome | 2019 |
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Topics: Acetamides; Adult; Antihypertensive Agents; Cardiac Surgical Procedures; Disease Progression; Double-Blind Method; Drug Monitoring; Early Medical Intervention; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Proportional Hazards Models; Pyrazines; Treatment Outcome | 2019 |
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
Topics: Acetamides; Adolescent; Adult; Aged; Antihypertensive Agents; Arterial Pressure; Biomarkers; Double-Blind Method; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2019 |
Pharmacotherapy for pulmonary arterial hypertension.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines; Pyrimidines; Severity of Illness Index; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance | 2020 |
Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
Topics: Acetamides; Administration, Intravenous; Administration, Oral; Aged; Antihypertensive Agents; Cross-Over Studies; Drug Administration Routes; Female; Headache; Humans; Male; Middle Aged; Prospective Studies; Pulmonary Arterial Hypertension; Pyrazines | 2021 |
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Male; Middle Aged; Morbidity; Prognosis; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Survival Rate | 2021 |
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyrazines; Pyrimidines; Sulfonamides; Tadalafil | 2021 |
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines | 2022 |
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
Topics: Acetamides; Antihypertensive Agents; Comorbidity; Double-Blind Method; Heart Failure; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines | 2022 |
Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
Topics: Acetamides; Antihypertensive Agents; Chronic Disease; Dyspnea; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Pyrazines; Treatment Outcome | 2022 |
68 other study(ies) available for pyrazines and selexipag
| Article | Year |
|---|---|
2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug.
Topics: Acetamides; Administration, Oral; Animals; Dogs; Femur; Half-Life; Humans; Male; Prodrugs; Pyrazines; Rats; Receptors, Epoprostenol; Regional Blood Flow; Vascular Diseases; Vasodilation | 2007 |
Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist.
Topics: Acetamides; Animals; Dogs; Drug Evaluation, Preclinical; Epoprostenol; Haplorhini; Humans; Male; Microsomes; Molecular Structure; Platelet Aggregation Inhibitors; Prodrugs; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Sulfonylurea Compounds | 2007 |
A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active fo
Topics: Acetamides; Acetates; Animals; Antihypertensive Agents; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; In Vitro Techniques; Male; Prodrugs; Pulmonary Artery; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Vasodilation | 2008 |
Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
Topics: Acetamides; Animals; Dinoprostone; Dose-Response Relationship, Drug; Epoprostenol; Gastric Emptying; Gastrointestinal Transit; Humans; Iloprost; Male; Muscle Contraction; Pulmonary Artery; Pyrazines; Rats; Receptors, Epoprostenol; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach | 2010 |
Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
Topics: Acetamides; Acetates; Alprostadil; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Epoprostenol; Hypertension, Pulmonary; In Vitro Techniques; Male; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar; Receptors, Epoprostenol; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2012 |
[Pulmonary hypertension].
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Benzamides; Drug Therapy, Combination; Early Medical Intervention; Epoprostenol; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Pyrazines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides | 2012 |
Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
Topics: Acetamides; Acetates; Animals; Benzofurans; Benzyl Compounds; Epoprostenol; Female; Iloprost; Imidazoles; Male; Propionates; Pulmonary Artery; Pulmonary Veins; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Vasodilation | 2013 |
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Animals; CHO Cells; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cricetulus; Dogs; Double-Blind Method; Haplorhini; Humans; Hypertension, Pulmonary; Myocytes, Smooth Muscle; Platelet Aggregation Inhibitors; Pulmonary Artery; Pyrazines; Randomized Controlled Trials as Topic; Rats; Receptors, Epoprostenol; Structure-Activity Relationship | 2015 |
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pyrazines | 2016 |
Selexipag (Uptravi) for pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Drug Interactions; Humans; Hypertension, Pulmonary; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Epoprostenol; Receptors, Prostaglandin; Tablets; Treatment Outcome | 2016 |
Prostaglandin I2 Receptor Agonism Preserves β-Cell Function and Attenuates Albuminuria Through Nephrin-Dependent Mechanisms.
Topics: Acetamides; Acetates; Animals; Cell Line; Cell Survival; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Membrane Proteins; Mice, Inbred C57BL; Mice, Knockout; Mutation; Phosphorylation; Podocytes; Prodrugs; Protein Processing, Post-Translational; Pyrazines; Receptors, Epoprostenol; Renal Insufficiency; RNA Interference | 2016 |
A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonar
Topics: Acetamides; Acetates; Animals; Cyclic AMP; Endothelium, Vascular; Humans; Male; Nitric Oxide; Pulmonary Artery; Pyrazines; Rats; Receptors, Epoprostenol; Swine; Vasodilation; Vasodilator Agents | 2017 |
Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys.
Topics: Acetamides; Animals; Antihypertensive Agents; Dogs; Intestinal Absorption; Macaca fascicularis; Pyrazines; Rats; Receptors, Epoprostenol; Species Specificity; Tissue Distribution | 2018 |
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Topics: Acetamides; Acetates; Animals; beta-Arrestins; Cell Proliferation; CHO Cells; Contractile Proteins; Cricetinae; Cricetulus; Cyclic AMP; Epoprostenol; Extracellular Matrix; Humans; Hypertension, Pulmonary; Iloprost; Male; Muscle Contraction; Muscle Relaxation; Pyrazines; Rats; Rats, Inbred SHR; Rats, Wistar; Receptors, Epoprostenol | 2017 |
Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
Topics: Acetamides; Administration, Oral; Adult; Antihypertensive Agents; Chronic Disease; Epoprostenol; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Paraplegia; Pyrazines; Severity of Illness Index; Ventricular Dysfunction, Right | 2017 |
Single-Center Experience Using Selexipag in a Pediatric Population.
Topics: Acetamides; Adolescent; Antihypertensive Agents; Child; Epoprostenol; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pyrazines; Treatment Outcome; Walk Test; Young Adult | 2017 |
Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension.
Topics: Acetamides; Child; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames).
Topics: Acetamides; Adult; Humans; Pyrazines; Raynaud Disease; Scleroderma, Systemic; Sugars | 2017 |
New Drugs 2017, part 3.
Topics: Acetamides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitoxins; Bridged Bicyclo Compounds, Heterocyclic; Carbazoles; Chenodeoxycholic Acid; Drug Approval; Humans; Indoles; Morpholinos; Oligonucleotides; Piperidines; Polydeoxyribonucleotides; Pyrazines; Sulfonamides; United States; United States Food and Drug Administration | 2017 |
Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
Topics: Acetamides; Adult; Antihypertensive Agents; Drug Therapy, Combination; Epoprostenol; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Humans; Prospective Studies; Pyrazines; Pyrimidines; Sulfonamides | 2017 |
Cross-species comparison of the metabolism and excretion of selexipag.
Topics: Acetamides; Acetates; Animals; Bile; Body Fluids; Chromatography, High Pressure Liquid; Dogs; Hepatocytes; Macaca fascicularis; Metabolome; Microsomes, Liver; Pyrazines; Rats; Rats, Sprague-Dawley; Species Specificity | 2019 |
Reply.
Topics: Acetamides; Adult; Humans; Pyrazines; Raynaud Disease; Scleroderma, Systemic | 2018 |
Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al.
Topics: Acetamides; Adult; Humans; Pyrazines; Raynaud Disease; Scleroderma, Systemic | 2018 |
Safety concerns regarding selexipag in pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pyrazines | 2018 |
Safety concerns regarding selexipag in pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pyrazines; Risk Evaluation and Mitigation | 2018 |
Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.
Topics: Acetamides; Animals; Epoprostenol; Femoral Artery; Male; Pyrazines; Rats; Rats, Wistar; Receptors, Epoprostenol; Receptors, Prostaglandin E, EP3 Subtype; Vasoconstriction | 2018 |
Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts.
Topics: Acetamides; Acetates; Actins; Aged; Cells, Cultured; Female; Fibroblasts; Gene Expression; Humans; Middle Aged; Muscle, Smooth; Myofibroblasts; Pyrazines; S100 Calcium-Binding Protein A4; Scleroderma, Systemic; Skin | 2018 |
Treatment of rat congenital diaphragmatic hernia with sildenafil and NS-304, selexipag's active compound, at the pseudoglandular stage improves lung vasculature.
Topics: Acetamides; Animals; Drug Therapy, Combination; Hernias, Diaphragmatic, Congenital; Humans; Lung; Pyrazines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate | 2018 |
Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.
Topics: Acetamides; Antihypertensive Agents; Drug Substitution; Drug Therapy, Combination; Epoprostenol; Female; Humans; Infusion Pumps; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Tadalafil; Vasodilator Agents | 2019 |
Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag In Vitro.
Topics: Acetamides; Antihypertensive Agents; Carboxylesterase; Carboxylic Ester Hydrolases; Humans; Hydrolysis; Intestinal Mucosa; Intestines; Kinetics; Liver; Pyrazines | 2019 |
Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Topics: Acetamides; Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Drug Substitution; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Male; Middle Aged; Pyrazines | 2018 |
Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
Topics: Acetamides; Decision Making; Decision Support Techniques; Humans; Hypertension, Pulmonary; Pyrazines; Quality of Life; Rare Diseases; Spain | 2018 |
Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Drug Substitution; Epoprostenol; Equipment Design; Female; Humans; Middle Aged; Monitoring, Physiologic; Prodrugs; Pulmonary Arterial Hypertension; Pulmonary Artery; Pulmonary Wedge Pressure; Pyrazines; Remote Sensing Technology | 2019 |
Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag.
Topics: Acetamides; Administration, Oral; Cardiac Catheterization; Drug Substitution; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Pyrazines | 2019 |
Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Topics: Acetamides; Aged; Antihypertensive Agents; Chronic Disease; Cohort Studies; Drug Therapy, Combination; Echocardiography; Endothelin Receptor Antagonists; Enzyme Activators; Exercise Test; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Oxygen Consumption; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Embolism; Pyrazines; Quality of Life; Retrospective Studies; Soluble Guanylyl Cyclase; Tricuspid Valve; Walk Test | 2019 |
Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
Topics: Acetamides; Administration, Intravenous; Administration, Oral; Antihypertensive Agents; Echocardiography; Enteral Nutrition; Epoprostenol; Humans; Infant, Newborn; Infusions, Intravenous; Male; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Receptors, Prostaglandin | 2019 |
Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Epoprostenol; Female; Goiter; Graves Disease; Hashimoto Disease; Humans; Hyperthyroidism; Male; Pulmonary Arterial Hypertension; Pyrazines; Thyroiditis, Autoimmune; Thyrotoxicosis | 2019 |
Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
Topics: Acetamides; Antihypertensive Agents; Arterial Pressure; Drug Substitution; Feasibility Studies; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Prospective Studies; Prostaglandins I; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Receptors, Epoprostenol; Time Factors; Treatment Outcome | 2020 |
Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution.
Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Pulmonary Arterial Hypertension; Pyrazines | 2020 |
NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
Topics: Acetamides; Animals; Antihypertensive Agents; Disease Models, Animal; Heart Ventricles; Hemodynamics; Humans; Hypertrophy, Right Ventricular; Male; Monocrotaline; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Rats; Rats, Inbred WKY; Receptors, Thromboxane; Sildenafil Citrate; Vascular Remodeling | 2020 |
Selexipag Use in Clinical Practice: Mind the Gap.
Topics: Acetamides; Consensus; Epoprostenol; Humans; Prostaglandins I; Pulmonary Arterial Hypertension; Pyrazines | 2020 |
Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Blood Pressure; Child; Female; Humans; Male; Prodrugs; Prospective Studies; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Treatment Outcome | 2020 |
[Experience with Selexipag to Treat Pulmonary Arterial Hypertension].
Topics: Acetamides; Humans; Pulmonary Arterial Hypertension; Pyrazines | 2020 |
Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.
Topics: Acetamides; Clopidogrel; Cytochrome P-450 CYP2C8; Drug Interactions; Healthy Volunteers; Humans; Male; Pyrazines | 2021 |
Use of selexipag in a child with pulmonary hypertension associated with sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Antihypertensive Agents; Child; Female; Humans; Hypertension, Pulmonary; Prodrugs; Pulmonary Wedge Pressure; Pyrazines | 2020 |
Rosacea induced by selexipag in a patient with pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Humans; Pulmonary Arterial Hypertension; Pyrazines; Rosacea | 2020 |
Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Topics: Acetamides; Administration, Intravenous; Administration, Oral; Aged; Antihypertensive Agents; Blood Pressure; Drug Substitution; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Pyrazines; Time Factors | 2020 |
Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?
Topics: Acetamides; Adolescent; Antihypertensive Agents; Asymptomatic Diseases; Bone Morphogenetic Protein Receptors, Type II; Cardiac Catheterization; Disease Progression; Dyspnea; Echocardiography; Exercise Tolerance; Female; Genetic Testing; Heterozygote; Humans; Male; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Syncope; Vasodilator Agents | 2020 |
Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method.
Topics: Acetamides; Acetates; Animals; Chromatography, High Pressure Liquid; Chromatography, Liquid; Pyrazines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2020 |
Potential of Selexipag in Chronic Thromboembolic Pulmonary Hypertension Medical Therapy.
Topics: Acetamides; Double-Blind Method; Humans; Hypertension, Pulmonary; Japan; Pyrazines | 2020 |
A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
Topics: Acetamides; Antihypertensive Agents; Female; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines | 2021 |
Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers.
Topics: Acetamides; Area Under Curve; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Japan; Pharmaceutical Preparations; Pyrazines | 2021 |
The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetamides; Animals; Cell Proliferation; Collagen Type I; Disease Models, Animal; Heart Ventricles; Hemodynamics; Hypertrophy, Right Ventricular; Hypoxia; Indoles; Lung; Male; Pulmonary Arterial Hypertension; Pyrazines; Pyrroles; Rats, Sprague-Dawley; Receptors, Epoprostenol; Systole; Vascular Remodeling | 2020 |
Prostaglandin I2 (PGI
Topics: Acetamides; Animals; Brucella abortus; Brucellosis; Cyclooxygenase 2; Cytochrome P-450 Enzyme System; Epoprostenol; Female; Humans; Macrophages; Mice; Pyrazines; RAW 264.7 Cells; Receptors, Epoprostenol; Signal Transduction; Specific Pathogen-Free Organisms | 2021 |
Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
Topics: Acetamides; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Prospective Studies; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Receptors, Prostaglandin; Treatment Outcome; United States | 2021 |
Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
Topics: Acetamides; Adult; Antihypertensive Agents; Eisenmenger Complex; Female; Humans; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines; Receptors, Epoprostenol | 2021 |
Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients.
Topics: Acetamides; Adult; Antihypertensive Agents; Child; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Pyrazines | 2021 |
Development of an efficient stability-indicating LC-MS/MS method for the analysis of selexipag and characterization of its degradation products.
Topics: Acetamides; Chromatography, High Pressure Liquid; Drug Contamination; Linear Models; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2021 |
Selexipag Therapy for Raynaud Phenomenon-induced Severe Digital Ischemia in Intravenous Epoprostenol Responders With Connective Tissue Disease.
Topics: Acetamides; Antihypertensive Agents; Connective Tissue Diseases; Epoprostenol; Humans; Ischemia; Pyrazines; Raynaud Disease | 2021 |
[Triple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III)].
Topics: Acetamides; Antihypertensive Agents; Familial Primary Pulmonary Hypertension; Female; Humans; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides | 2021 |
Selexipag and the pulmonary hypertension continuum.
Topics: Acetamides; Heart Failure; Humans; Hypertension, Pulmonary; Pyrazines | 2022 |
Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles.
Topics: Acetamides; Acetates; Animals; Antihypertensive Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C8 Inhibitors; Dogs; Female; Herb-Drug Interactions; Male; Pyrazines; Quercetin; Tandem Mass Spectrometry | 2022 |
Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
Topics: Acetamides; Adult; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Iloprost; Lupus Erythematosus, Systemic; Pulmonary Arterial Hypertension; Pyrazines; Quality of Life | 2022 |
Selexipag Improves Lipopolysaccharide-Induced ARDS on C57BL/6 Mice by Modulating the cAMP/PKA and cAMP/Epac1 Signaling Pathways.
Topics: Acetamides; Animals; Inflammation; Lipopolysaccharides; Lung; Mice; Mice, Inbred C57BL; Pyrazines; Respiratory Distress Syndrome; Signal Transduction | 2022 |
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough.
Topics: Acetamides; Humans; Hypertension, Pulmonary; Pyrazines | 2022 |
Case report: apatinib plus selexipag as a novel therapy for pulmonary tumor thrombotic microangiopathy accompanied by pulmonary hypertension associated with gastric carcinoma.
Topics: Acetamides; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Lung Neoplasms; Middle Aged; Pulmonary Artery; Pyrazines; Pyridines; Receptors, Epoprostenol; Receptors, Vascular Endothelial Growth Factor; Stomach Neoplasms; Thrombotic Microangiopathies | 2022 |
Validation of the new paediatric pulmonary hypertension risk score by CMR and speckle tracking echocardiography.
Topics: Acetamides; Child; Echocardiography; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Pyrazines; Risk Factors; Young Adult | 2022 |
Effectiveness and persistence with selexipag in pulmonary arterial hypertension in the real-life setting.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines | 2023 |